EMA Authorised: Imbruvica (Ibrutinib) — Janssen-Cilag International NV

View source ↗

Summary

EMA authorised Imbruvica (ibrutinib) for mantle cell lymphoma and chronic lymphocytic leukemia, with Janssen-Cilag International NV as the marketing authorizati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Mantle-Cell;Leukemia, Lymphocytic, Chronic, B-Cell. MAH: Janssen-Cilag International NV. Decision date: 13/02/2026